Article
A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity.
Drug metabolism and disposition: the biological fate of chemicals - 1 Jun 2012
Shimizu Mai, Fukami Tatsuki, Kobayashi Yuki, Takamiya Masataka, Aoki Yasuhiro, Nakajima Miki, Yokoi Tsuyoshi
Abstract excerpt
Human arylacetamide deacetylase (AADAC) is responsible for the hydrolysis of clinically used drugs such as flutamide, phenacetin, and rifamycins. Our recent studies suggested that human AADAC is a relevant enzyme pharmacologically and toxicologically. To date, the genetic polymorphisms that affect enzyme activity in AADAC have been unknown. In this study, we found single-nucleotide polymorphisms in the human...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.